Although FGFR1 or FGFR2 amplifications and mutations are frequent in non-small cell lung, breast, endometrial and gastric cancer11–13, intrahepatic cholangiocarcinoma is more prone to have FGFR2 gene fusions14. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.